Pharvaris Shares Exciting Updates on Deucrictibant Program
Pharvaris, a biopharmaceutical company dedicated to developing therapies for hereditary angioedema (HAE), is making notable progress in its deucrictibant development program. One of the most noteworthy announcements is the upcoming launch of CHAPTER-3, a crucial Phase 3 clinical trial aimed at assessing the safety and efficacy of deucrictibant in patients with HAE. This global study is expected to commence by the end of 2024.
Overview of the CHAPTER-3 Study
CHAPTER-3 will concentrate on the prophylactic treatment of HAE using an extended-release formulation of deucrictibant. This method is intended to provide patients with lasting protection from HAE attacks by ensuring therapeutic plasma levels for more than 24 hours. Pharvaris states that the study's goal is to validate the benefits of once-daily dosing and its potential to enhance the quality of life for those living with HAE.
Anticipated Impact and Future Plans
Pharvaris is also eager to investigate the potential of deucrictibant for treating acquired angioedema (AAE-C1INH). This demonstrates the company's dedication to tackling various types of bradykinin-mediated diseases. Such initiatives underscore Pharvaris's ambition to provide comprehensive care for angioedema patients and significantly broaden the therapeutic options available.
Positive Feedback from the Medical Community
Berndt Modig, the CEO of Pharvaris, shared his optimism regarding the future of deucrictibant, referencing recent data that highlights its efficacy and tolerability in both preventative and on-demand treatment scenarios. Upcoming presentations at the 2024 Bradykinin Symposium will further highlight the distinctive profile of deucrictibant, with the aim of establishing it as a preferred treatment for managing HAE.
Clinical Evidence Supporting Deucrictibant
The growing body of evidence backing the use of deucrictibant is drawing attention. Recent results from investigator-initiated trials have shown that deucrictibant effectively reduces the frequency of HAE attacks while maintaining a favorable safety profile. As ongoing studies continue to produce positive findings, Pharvaris seeks to solidify deucrictibant’s role in the treatment landscape for HAE.
Engagement with Stakeholders
In line with its commitment to transparency and open communication, Pharvaris plans to host a conference call to provide detailed updates. During this session, stakeholders will have the chance to learn more about the company's initiatives and ask questions regarding its ongoing studies and future plans.
About Pharvaris and Deucrictibant
Pharvaris specializes in the development of oral bradykinin B2 receptor antagonists, with deucrictibant leading the charge. Through this innovative approach, Pharvaris aims to deliver effective and well-tolerated alternatives for managing angioedema, targeting not only HAE but also AAE due to C1-inhibitor deficiency. With plans for clinical expansions and strong supporting data, Pharvaris is positioning itself as a leader in the management of bradykinin-mediated angioedema.
Frequently Asked Questions
What is deucrictibant?
Deucrictibant is an oral bradykinin B2 receptor antagonist developed by Pharvaris for treating hereditary angioedema (HAE) and acquired angioedema (AAE).
What is the CHAPTER-3 study?
CHAPTER-3 is a pivotal Phase 3 clinical study designed to evaluate the efficacy and safety of deucrictibant for the prophylactic treatment of HAE, set to begin by the end of 2024.
How does deucrictibant work?
Deucrictibant works by inhibiting bradykinin signaling, which helps prevent HAE attacks and manage symptoms when they occur.
What are the key goals of Pharvaris regarding deucrictibant?
Pharvaris aims to establish deucrictibant as a preferred therapy for HAE treatment and explore its application in treating acquired angioedema, thereby enhancing patient options.
When will Pharvaris provide further updates on deucrictibant?
Pharvaris is expected to share updates during their upcoming conference call and presentations at the Bradykinin Symposium and other medical conferences.
